OrbiMed — 2019 Investments

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

JGJames G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Board seatDBDavid Bonita· per SEC Form D

Co-investorsBABay City CapitalNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsRARA CapitalALAlexandriaARArix Bioscience+3 more

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)inPLPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019

Co-investorsNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsCOCorrelation VenturesOUOUP (Osage University Partners)PFPfizer VenturesSOSofinnova Ventures

RECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts.

BiotechHealthtechMedical DevicesMelbourne, US

Fiona WoodDADale A Sander(Executive Officer)inCVCary Vance(Executive Chairman & Interim Chief Executive Officer)in

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

WCWilliam Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)SSStephen Squinto(Executive Officer, Director)in

BoardPHPatrick Heron(Director)inCGCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFRFrazier Life SciencesACAccess BiotechnologyFRFrazier Healthcare PartnersLILilly Asia VenturesNENew Leaf Venture PartnersSPSphera Funds Management+2 more

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.

BiotechHealthtechMedical DevicesSan Francisco, US

SGSevgi Gurkan(Founder, Chief Executive Officer, and Member of the Board of Directors)in

BoardChristy Shaffer(Director)

Board seatChau Khuong· per SEC Form D

Co-investorsACAccess BiotechnologyCACatalio Capital Management, LPHAHatteras Venture PartnersLALAVLILilly Asia VenturesHAHatteras

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong, US

Aleksandrs Zavoronkovs(Executive Officer, Director)AZAlex Zavoronkov(Director)AZAlex Zhavoronkov(Founder)inAAAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

BoardNLNisa Leung(Director)in

Co-investorsLILilly Asia VenturesQIQiming Venture PartnersWAWarburg PincusBABaidu VenturesEIEight Roads VenturesLALake Bleu Capital+15 more

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.

BiotechHealthtechMental HealthMilwaukee, US

DBDavid Baker, PhD(Director)DLDaniel Lawton(Executive Officer, Director)TBTom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)

Board seatKVKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019

Co-investorsAIAisling CapitalF-F-Prime Capital

AirStrip develops clinical decision support and patient monitoring software, including data-driven and AI predictive analytics tools, for hospitals, health systems, and clinicians.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaSSan Antonio, US

APAlan Portela(Executive Officer, Director)inDr. Naseem(Chief Executive Officer)LSLauren Schiegg(Chief Operating Officer)inHRHari Radhakrishnan(Chief Medical Officer)inSHSken Huang(Chief Financial Officer)inRory(Chief Commercial Officer)

BiotechBuffalo, US

Flint Besecker(Executive Officer, Director)inLi Shen(Executive Officer)inSimon Pedder(Executive Officer)inJohnson Lau(Executive Officer, Director)inWilliam Zuo(Executive Officer)Rudolf Kwan(Executive Officer)

Co-investorsAVAvoro Capital AdvisorsSASalica Investments

Avedro is an ophthalmic company focused on corneal health, known for bio-activated cross-linking therapies such as the KXL system and riboflavin-based treatments used to address progressive keratoconus.

BiotechHealthtechMedical DevicesWaltham, US

David F. Muller(Executive Officer, Director)inBJBrian J. Roberts(Executive Officer)inRJRhonda J. Bracey(Executive Officer)inThomas W. Burns(Chairman & Chief Executive Officer)

BoardJason Hong(Director)JDJeff Dykan(Director)in

Co-investorsAPAPERTURE Venture PartnersLALAVLILilly Asia VenturesSCSCP Vitalife PartnersTHThird Point VenturesWEWestern Technology Investment+5 more

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

JVJohn Valliant(Founder)in

Co-investorsFAFACIT (Fight Against Cancer Innovation Trust)GEGenesys CapitalHEHealthCapLULumira VenturesPIPivotal Life SciencesSESeroba Life Sciences+6 more

This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.

Biotech

Co-investorsCDCDP Venture CapitalIRIreland Strategic Investment FundADAdams Street PartnersGEGenesys CapitalHEHealthCapPIPivotal Life Sciences+1 more

Co-investorsATAtlas VentureBABain Capital Life SciencesGEGeneral Atlantic